Mucosal Vaccine Approaches for Prevention of HIV and SIV Transmission

Overview

Journal Curr Immunol Rev

Publisher Bentham Science Publishers

Specialty Allergy & Immunology

Date 2019 Aug 28

PMID 31452652

Citations 20

Authors

Pamela A Kozlowski

Anna Aldovini

Affiliations

Soon will be listed here.

Abstract

Optimal protective immunity to HIV will likely require that plasma cells, memory B cells and memory T cells be stationed in mucosal tissues at portals of viral entry. Mucosal vaccine administration is more effective than parenteral vaccine delivery for this purpose. The challenge has been to achieve efficient vaccine uptake at mucosal surfaces, and to identify safe and effective adjuvants, especially for mucosally administered HIV envelope protein immunogens. Here, we discuss strategies used to deliver potential HIV vaccine candidates in the intestine, respiratory tract, and male and female genital tract of humans and nonhuman primates. We also review mucosal adjuvants, including Toll-like receptor agonists, which may adjuvant both mucosal humoral and cellular immune responses to HIV protein immunogens.

Citing Articles

Induction of Tier 2 HIV-Neutralizing IgA Antibodies in Rhesus Macaques Vaccinated with BG505.664 SOSIP.

Smith J, Arunachalam P, Legere T, Cavacini L, Hunter E, Pulendran B Vaccines (Basel). 2025; 12(12.

PMID: 39772048 PMC: 11680376. DOI: 10.3390/vaccines12121386.

Alcaligenes lipid A functions as a superior mucosal adjuvant to monophosphoryl lipid A via the recruitment and activation of CD11b+ dendritic cells in nasal tissue.

Sun X, Hosomi K, Shimoyama A, Yoshii K, Saika A, Yamaura H Int Immunol. 2023; 36(1):33-43.

PMID: 38006376 PMC: 10823578. DOI: 10.1093/intimm/dxad045.

The initial interplay between HIV and mucosal innate immunity.

Caputo V, Libera M, Sisti S, Giuliani B, Diotti R, Criscuolo E Front Immunol. 2023; 14:1104423.

PMID: 36798134 PMC: 9927018. DOI: 10.3389/fimmu.2023.1104423.

Development of mucosal vaccine delivery: an overview on the mucosal vaccines and their adjuvants.

Anggraeni R, Ana I, Wihadmadyatami H Clin Exp Vaccine Res. 2022; 11(3):235-248.

PMID: 36451668 PMC: 9691869. DOI: 10.7774/cevr.2022.11.3.235.

Mucosal Delivery of HIV-1 Glycoprotein Vaccine Candidate Enabled by Short Carbon Nanotubes.

Xu Y, Jiang X, Zhou Z, Ferguson T, Obliosca J, Luo C Part Part Syst Charact. 2022; 39(5).

PMID: 36186663 PMC: 9523582. DOI: 10.1002/ppsc.202200011.

References

Kantele A, Hakkinen M, Moldoveanu Z, Lu A, Savilahti E, Alvarez R . Differences in immune responses induced by oral and rectal immunizations with Salmonella typhi Ty21a: evidence for compartmentalization within the common mucosal immune system in humans. Infect Immun. 1998; 66(12):5630-5. PMC: 108711. DOI: 10.1128/IAI.66.12.5630-5635.1998. View

Hayashi M, Aoshi T, Ozasa K, Kusakabe T, Momota M, Haseda Y . RNA is an Adjuvanticity Mediator for the Lipid-Based Mucosal Adjuvant, Endocine. Sci Rep. 2016; 6:29165. PMC: 4931589. DOI: 10.1038/srep29165. View

Wira C, Fahey J, Sentman C, Pioli P, Shen L . Innate and adaptive immunity in female genital tract: cellular responses and interactions. Immunol Rev. 2005; 206:306-35. DOI: 10.1111/j.0105-2896.2005.00287.x. View

Pialoux G, Hocini H, Perusat S, Silberman B, Salmon-Ceron D, Slama L . Phase I study of a candidate vaccine based on recombinant HIV-1 gp160 (MN/LAI) administered by the mucosal route to HIV-seronegative volunteers: the ANRS VAC14 study. Vaccine. 2007; 26(21):2657-66. DOI: 10.1016/j.vaccine.2007.11.002. View

Deli M . Potential use of tight junction modulators to reversibly open membranous barriers and improve drug delivery. Biochim Biophys Acta. 2008; 1788(4):892-910. DOI: 10.1016/j.bbamem.2008.09.016. View

Caputo S, Trabattoni D, Vichi F, Piconi S, Lopalco L, Villa M . Mucosal and systemic HIV-1-specific immunity in HIV-1-exposed but uninfected heterosexual men. AIDS. 2003; 17(4):531-9. DOI: 10.1097/00002030-200303070-00008. View

Riddle M, Kaminski R, Williams C, Porter C, Baqar S, Kordis A . Safety and immunogenicity of an intranasal Shigella flexneri 2a Invaplex 50 vaccine. Vaccine. 2011; 29(40):7009-19. DOI: 10.1016/j.vaccine.2011.07.033. View

Manrique M, Kozlowski P, Cobo-Molinos A, Wang S, Wilson R, Martinez-Viedma M . Resistance to infection, early and persistent suppression of simian immunodeficiency virus SIVmac251 viremia, and significant reduction of tissue viral burden after mucosal vaccination in female rhesus macaques. J Virol. 2013; 88(1):212-24. PMC: 3911749. DOI: 10.1128/JVI.02523-13. View

Fenizia C, Rossignol J, Clerici M, Biasin M . Genetic and immune determinants of immune activation in HIV-exposed seronegative individuals and their role in protection against HIV infection. Infect Genet Evol. 2017; 66:325-334. DOI: 10.1016/j.meegid.2017.12.014. View

10.

Anjuere F, Bekri S, Bihl F, Braud V, Cuburu N, Czerkinsky C . B cell and T cell immunity in the female genital tract: potential of distinct mucosal routes of vaccination and role of tissue-associated dendritic cells and natural killer cells. Clin Microbiol Infect. 2012; 18 Suppl 5:117-22. DOI: 10.1111/j.1469-0691.2012.03995.x. View

11.

Wang S, Villablanca E, De Calisto J, Gomes D, Nguyen D, Mizoguchi E . MyD88-dependent TLR1/2 signals educate dendritic cells with gut-specific imprinting properties. J Immunol. 2011; 187(1):141-50. PMC: 3119749. DOI: 10.4049/jimmunol.1003740. View

12.

Chabot S, Wagner J, Farrant S, Neutra M . TLRs regulate the gatekeeping functions of the intestinal follicle-associated epithelium. J Immunol. 2006; 176(7):4275-83. DOI: 10.4049/jimmunol.176.7.4275. View

13.

Barouch D, Craiu A, Kuroda M, Schmitz J, Zheng X, Santra S . Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. Proc Natl Acad Sci U S A. 2000; 97(8):4192-7. PMC: 18194. DOI: 10.1073/pnas.050417697. View

14.

Bolton D, Santra S, Swett-Tapia C, Custers J, Song K, Balachandran H . Priming T-cell responses with recombinant measles vaccine vector in a heterologous prime-boost setting in non-human primates. Vaccine. 2012; 30(41):5991-8. PMC: 3425710. DOI: 10.1016/j.vaccine.2012.06.029. View

15.

Mohideen M, Quijano E, Song E, Deng Y, Panse G, Zhang W . Degradable bioadhesive nanoparticles for prolonged intravaginal delivery and retention of elvitegravir. Biomaterials. 2017; 144:144-154. PMC: 5581224. DOI: 10.1016/j.biomaterials.2017.08.029. View

16.

Rudin A, Johansson E, Bergquist C, Holmgren J . Differential kinetics and distribution of antibodies in serum and nasal and vaginal secretions after nasal and oral vaccination of humans. Infect Immun. 1998; 66(7):3390-6. PMC: 108357. DOI: 10.1128/IAI.66.7.3390-3396.1998. View

17.

Clements J, Freytag L . Parenteral Vaccination Can Be an Effective Means of Inducing Protective Mucosal Responses. Clin Vaccine Immunol. 2016; 23(6):438-441. PMC: 4895008. DOI: 10.1128/CVI.00214-16. View

18.

Sui Y, Zhu Q, Gagnon S, Dzutsev A, Terabe M, Vaccari M . Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques. Proc Natl Acad Sci U S A. 2010; 107(21):9843-8. PMC: 2906837. DOI: 10.1073/pnas.0911932107. View

19.

Boyer J, Robinson T, Maciag P, Peng X, Johnson R, Pavlakis G . DNA prime Listeria boost induces a cellular immune response to SIV antigens in the rhesus macaque model that is capable of limited suppression of SIV239 viral replication. Virology. 2005; 333(1):88-101. DOI: 10.1016/j.virol.2004.12.026. View

20.

Gallorini S, Taccone M, Bonci A, Nardelli F, Casini D, Bonificio A . Sublingual immunization with a subunit influenza vaccine elicits comparable systemic immune response as intramuscular immunization, but also induces local IgA and TH17 responses. Vaccine. 2014; 32(20):2382-8. DOI: 10.1016/j.vaccine.2013.12.043. View